COMPASS Pathways’ (CMPS) “Outperform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $18.00 price objective on the stock.

A number of other brokerages also recently weighed in on CMPS. HC Wainwright lowered their price objective on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Maxim Group lowered their price objective on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $33.60.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock opened at $3.49 on Wednesday. The firm has a market cap of $238.79 million, a PE ratio of -1.59 and a beta of 2.27. The firm’s 50-day simple moving average is $4.32 and its 200-day simple moving average is $5.87. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. COMPASS Pathways has a 1 year low of $3.16 and a 1 year high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter last year, the business posted ($0.67) earnings per share. Equities analysts forecast that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CMPS. Green Alpha Advisors LLC bought a new position in COMPASS Pathways in the 3rd quarter worth about $99,000. Y Intercept Hong Kong Ltd bought a new position in shares of COMPASS Pathways in the third quarter valued at approximately $131,000. Geode Capital Management LLC boosted its holdings in shares of COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after acquiring an additional 25,970 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of COMPASS Pathways in the third quarter valued at approximately $371,000. Finally, Propel Bio Management LLC bought a new position in shares of COMPASS Pathways in the third quarter valued at approximately $504,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.